Most Read Articles
Roshini Claire Anthony, 4 days ago

Abstaining from alcohol may reduce the risk of atrial fibrillation (AF) recurrence in individuals who regularly consume alcohol, according to a small study from Australia.

Pearl Toh, 4 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
11 Jan 2020
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.
04 Jan 2020
Hepatitis C virus (HCV) infection continues to be the leading indication of liver transplantation (LT) among patients with hepatocellular carcinoma (HCC), trailed by nonalcoholic steatohepatitis (NASH) and alcoholic liver disease (ALD), a recent study has found.

Product Highlight - Zavicefta

29 Nov 2019

Active ingredient: Ceftazidime (as pentahydrate) equivalent to 2 g and Avibactam (as sodium salt) equivalent to 0.5 g.

Indications: ZAVICEFTATM is indicated in adults for the treatment of the following infections

  • Complicated Intra-Abdominal Infection (cIAI)
  • Complicated Urinary Tract Infection, including Pyelonephritis (cUTI)
  • Hospital-acquired Pneumonia (HAP), including ventilator associated pneumonia (VAP)
  • Infections due to aerobic Gram-negative organisms in patients with limited treatment options
  • Consideration should be given to official guidance on the appropriate use of antibacterial agents. For treatment of cIAI use in combination with metronidazole.

Dosage & Administration: The recommended dosage of ZAVICEFTATM is 1 vial where each vial contains 2 g ceftazidime and 0.5 g avibactam administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes in patients aged 18 years or older. Treatment is repeated every 8 hours.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Thailand digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 4 days ago

Abstaining from alcohol may reduce the risk of atrial fibrillation (AF) recurrence in individuals who regularly consume alcohol, according to a small study from Australia.

Pearl Toh, 4 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
11 Jan 2020
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.
04 Jan 2020
Hepatitis C virus (HCV) infection continues to be the leading indication of liver transplantation (LT) among patients with hepatocellular carcinoma (HCC), trailed by nonalcoholic steatohepatitis (NASH) and alcoholic liver disease (ALD), a recent study has found.